But agents that inhibit postprandial glucagon secretion or antagonize glucagon action or inhibit glucagon receptor GCGRs have obvious side effects, such as hepatic steatosis, hyperlipidemia, and hyperaminoacidemia, could lead to more serious metabolic disorders and even serious cardiovascular diseases [49–51]. The gene discussed is GCGR; the disease is metabolic disease.